Gsk Share Discussion Threads

[tim 3] 27/10/2017 08:27

Nice one guys hope you are right.

[che7win] 27/10/2017 08:25

Moving up now guys, a few shorts to close, they won't want to pay the 19p dividend two weeks.

Play it to your advantage.

[essentialinvestor] 27/10/2017 08:23

Increased my holding by 20%. The extent of the fall has surprised me,
and I'm usually overly cautious on price.

[dr biotech] 27/10/2017 08:22

Well I have added 50% to my holding at 1356. Also opened a £20pp sb at a similar price with a stop at 1320. Fingers crossed

[uapatel] 27/10/2017 08:22

Not very clever on Emma's part if she was thinking of rights issue. Still if she tested the water with institutions already, probably explains the overtly large drop.(IMHO)

[tim 3] 27/10/2017 08:20

This is pretty relentless starting to look like a revaluation.

[che7win] 27/10/2017 08:18

Buying more.

[spoole5] 27/10/2017 08:16

the further the price falls the less chance she has of bidding for anything.

[mj19] 27/10/2017 07:57

Start auction for bidding in Nov for their consumer unit... how much will gsk be willing to pay and where will the money come from . Could she do a rights issue? Or cut the divi?

[essentialinvestor] 27/10/2017 00:46

Questions on the call were fair and reasonable, whether there was an
agenda is a different issue.

If the CEO indicates an interest in a potential $15 Billion acquisition,
it's more than reasonable to question funding re implications for
the dividend. Some would see it as remiss not to raise the question,
particularly given net debt levels.

Once you highlight the prospect of acquiring an asset, the following question was always going to be how is this funded.

[philanderer] 26/10/2017 23:58

'Pfizer to launch consumer health sale in November - sources'

[cyberian] 26/10/2017 23:29

First the WS after hours price for the ADR's rose to the equiv. of 1400p after a generally down day. However, too much excitment over the spoken interest over a full acquisition of Pfizer's consumer business, whereas I think GSK will position with others to grab just parts of the sector to be placed for possible auction in the market next month. The Novartis PUT option for the their remaining 35% (JV has proven to be very beneficial to GSK with the increased margins on revenues achieved) which could have a cost of £10 billion is stated to be unlikely to be triggered. Novartis appear happy to retain their 35% going forward. What has really happened since the 3Q results has been purely speculative (OK the CEO may have been railroaded a bit by analysts yesterday, but the current view is that some parties had an agenda to create a bad atmosphere and to encourage a negative bias for the SP, and they have succeeded. However the average broker price target and support still seems to be about 1600p or abit higher, just down a fraction. The fundamentals are still looking good and I have seen one analyst report from a highly rated name indicate a strong 4Q ahead, and pretty encouraging expectations into 2018. Sure the CEO is mindful of the dividend commitment, and will not likely to run the risk of upsetting the key Institutions whose support she needs to achieve managed growth going forward...she may have had a bit of a shock with the extent of the fall over the last 2 days in the share price The market may well have had its day of attack but difficult to look for more pain given the balance of the results..a few swings between sectors , but some quite positive news on some drugs approval ratings with huge potential revenue streams to follow. This year GSK value has fallen 3.5% whereas its peers have seen a rise of close to 17.5%..cant really see why the gap cannot be closed to some extent...we shall see.

[fangorn2] 26/10/2017 22:13

GlaxoSmithKline Q3 2017: Bear Signals

Summary

GlaxoSmithKline reported Q3 2017 results that were better than consensus…

…but the market has been disappointed by the performance of some key growth drivers in the Pharmaceutical Division.

Even if the stock has de-rated from 10x to 8.4 NTM EV/EBITDA, I see too many uncertainties on the 2018 outlook.




"Long myself - and topped up this morning on the dip"

[gripfit] 26/10/2017 21:45

im sticking with property, at least its fun ,,, dealing with dodgy peeps

[gripfit] 26/10/2017 21:42

so much for buying a safe stock,,, dividend hammered , capitol loss mullered, stick to what you know...

[zho] 26/10/2017 21:40

"Here’s how to knock £4bn off your market capitalisation in one swoop: say you’re having a look at buying a rival’s unwanted subsidiary but give no details as to how you would meet the likely $14bn-$15bn (£10.5bn-£11.3bn) bill."

[essentialinvestor] 26/10/2017 20:39

If J&J is involved the rest can forget it, as they can easily outbid
anyone given their financial firepower. Provided they want it.

[philanderer] 26/10/2017 20:35

Sanofi, J&J could join GlaxoSmithKline, Reckitt in $20B bidding war for Pfizer OTC: report

[romeike] 26/10/2017 19:59

The investor call was essentially hijacked by certain hostile analysts whose only interest was driving down the share price for their clients.

And I agree with NYB, the US market in particular is well overdue a trashing.

[ny boy] 26/10/2017 19:33

Better to have cashed tied up in blue chips, when the market turns South,the cream will rise to the top, as always. Better to collect 5%+ than sfa on deposit down at el banco.

[marksp2011] 26/10/2017 19:28

Whilst I dont expect a divi cut

"The Board intends to maintain the dividend for 2018 at the current level of 80p per share, subject to any material change in the external environment or performance expectations." Is hardly a great message... we will hold the divi for the next 5 quarters as long as nothing happens that makes us decide not to.

Follow that with " we intend to rebuild cover" suggests no divi growth for a while yet.

I am not shocked the share price has tanked. The words were a lot less supportive than the numbers. Too late now as it has overshot on the downside but that wasn't a good report and I have a reasonable amount of capital tied up in these

[ny boy] 26/10/2017 19:20

Not bothered where it goes short term, just using big pull backs to double up, happy collecting the annual 5.8% divi, paid quarterley. GLA

[montyhedge] 26/10/2017 17:55

Figures good, naive CEO making stupid comment about bid. Emailed her telling to up her game and get street wise with the market. Bears put 2 and 2 together, bid=dividend cut to fund it, great bear attack.
Bounce in the morning.

[mj19] 26/10/2017 17:50

3.7% down in US

[philanderer] 26/10/2017 16:56

From earlier today..

Downgraded by BOA Merrill Lynch from 'buy' to 'neutral'

The US investment bank Merrill Lynch has graded GlaxoSmithKline from "buy" to neutral for the third quarter and lowered its price target from 1730 to 1550 pence. The US investment bank's experts explained their step in a study published on Thursday with the expectation of increasing pressure on margins from 2018 - partly because of the generic competition for the asthma drug Advair. In addition, the management of the pharmaceutical company did not want to exclude a dividend reduction./tih/ck Date of analysis: 26.10.2017